Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹7 Cr revenue.
COGS 0.0%, employees 312.9%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -97.7%▼ | 10.5% |
| ROCE | -97.1%▼ | 13.8% |
| Net Margin | -17.8%▼ | 8.7% |
| EBITDA Margin | -17.4%▼ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| Rev Growth 3yr | 0.8%▼ | 5.8% |
| EPS Growth 3yr | 9.7%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7 Cr +6.1% | ₹7 Cr -43.1% | ₹12 Cr -13.6% | ₹14 Cr +14.3% | ₹12 Cr -12.1% | ₹13 Cr -6.5% | ₹14 Cr -97.8% | ₹664 Cr |
| Other Income | ₹8 Cr -23.1% | ₹11 Cr -48.4% | ₹21 Cr +150.1% | ₹8 Cr +58.9% | ₹5 Cr -31.4% | ₹8 Cr -44.8% | ₹14 Cr -42.1% | ₹24 Cr |
| Total Income | ₹15 Cr -12.1% | ₹18 Cr -46.5% | ₹33 Cr +49.3% | ₹22 Cr +28.1% | ₹17 Cr -19.2% | ₹21 Cr -25.4% | ₹28 Cr -95.9% | ₹688 Cr |
| ₹290 Cr +62.7% | ₹178 Cr +21.8% | ₹146 Cr +0.1% | ₹146 Cr +5.1% | ₹139 Cr +41.0% | ₹99 Cr -26.8% | ₹135 Cr -74.5% | ₹529 Cr | |
| Profit Before Tax | (₹275 Cr) -70.9% | (₹161 Cr) -51.5% | (₹106 Cr) +10.3% | (₹118 Cr) +3.1% | (₹122 Cr) -57.5% | (₹77 Cr) +27.2% | (₹106 Cr) ↓ Decline | ₹159 Cr |
| Net Profit | (₹275 Cr) -70.9% | (₹161 Cr) -53.0% | (₹105 Cr) +11.2% | (₹118 Cr) +3.1% | (₹122 Cr) -69.1% | (₹72 Cr) +23.4% | (₹94 Cr) ↓ Decline | ₹87 Cr |
| Profit (Owners) | (₹275 Cr) -70.9% | (₹161 Cr) -53.0% | (₹105 Cr) +11.2% | (₹118 Cr) +3.1% | (₹122 Cr) -69.1% | (₹72 Cr) +23.4% | (₹94 Cr) ↓ Decline | ₹87 Cr |
| Other Comprehensive Income | (₹1 Cr) -120.7% | (₹0.58 Cr) -872.2% | (₹0.06 Cr) ↓ Decline | ₹0.19 Cr ↑ Recovery | (₹0.15 Cr) +50.9% | (₹0.31 Cr) -3.8% | (₹0.30 Cr) -114.5% | (₹0.14 Cr) |
| EPS | (₹12.26) | (₹7.37) | (₹4.82) | (₹5.42) | (₹5.59) | (₹3.78) | (₹4.93) | ₹4.55 |
| Diluted Shares | ₹23 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹19 Cr | ₹19 Cr | ₹19 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Suven Life Sciences announces successful completion and topline results of First-in-Human (F...
Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 12, 2026, titled "Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), includi...
Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled "Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Gl...
Suven Life Sciences Limited has informed the Exchange rectification order for assesment year 2020-21
Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the ma...
Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
Monitoring Agency Report for the quarter ended 31st March, 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Suven Life Sciences Limited has informed the Exchange regarding Grant of 133200 Options.
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502...
Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
Suven Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Suven Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 06, 2026 on ALLOTMENT OF 3,17,68,764 EQUITY SHARES OF THE COMPANY ON PREFERENTIAL BASIS
Suven Life Sciences Limited has informed the Exchange regarding allotment of 31768764 securities pursuant to Preferential Issue at its meeting held on March 06, 2026
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.